Soleno Therapeutics INC Schedule 13G passive stakes

NASDAQ

12 Feb 2025

SLNO

SCHEDULE 13G/A: Adage Capital Management Discloses 6.44% Stake in Soleno Therapeutics

Adage Capital Management, L.P. and its principals have filed an amended Schedule 13G, disclosing a beneficial ownership of 6.44% in Soleno Therapeutics Inc. as of December 31, 2024.

NASDAQ

6 Feb 2025

SLNO

Soleno Therapeutics INC

SCHEDULE 13G/A: BlackRock Discloses Reduced Stake in Soleno Therapeutics Below 5%

BlackRock, Inc. has filed an amended Schedule 13G, reporting its beneficial ownership in Soleno Therapeutics Inc. has decreased to 4.7% as of December 31, 2024.